中大機構典藏-NCU Institutional Repository-提供博碩士論文、考古題、期刊論文、研究計畫等下載:Item 987654321/6381
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 80990/80990 (100%)
造訪人次 : 40890166      線上人數 : 1085
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋


    請使用永久網址來引用或連結此文件: http://ir.lib.ncu.edu.tw/handle/987654321/6381


    題名: Nanog和Oct4表現對肌肉分化之影響;Effects of Nanog and Oct4 overexpression on myogenic differentiation
    作者: 黃苡甄;I-chen Huang
    貢獻者: 生命科學研究所
    關鍵詞: Nanog;Oct4
    日期: 2004-10-11
    上傳時間: 2009-09-22 10:18:33 (UTC+8)
    出版者: 國立中央大學圖書館
    摘要: 胚胎幹細胞可分化發育成生物個體的所有組織,究竟為何幹細胞能具有如此的特性而有別於體細胞?近來的研究,發現幹細胞當中存在著獨特的因子能維持其多能性,這些獨特的調控因子可藉由刺激或抑制其標的基因的表現來調節胚胎發育分化的過程。Nanog是一個近年來才被確定的基因,其在維持幹細胞獨特的特性扮演很重要的角色。而Oct4,亦命名為Oct3,是屬於POU家族中的其中一員,藉由和序列ATGCAAAT相互作用來調節其標的基因的表現。在這個實驗當中,我們要來探討,當Nanog或是Oct4大量表現在C2C12肌肉細胞時,是否能使得肌肉細胞重新具有多能性?利用反轉錄病毒來感染C2C12肌肉細胞,使其能夠穩定並且大量的表現Nanog或Oct4,以及同時表現兩者基因。我們發現,在Nanog的穩定表達細胞株於分化的狀態其形成的肌管數目僅僅為控制組的五分之一,其形成的肌管數目分別是59條/單位面積以及236條/單位面積。在形態上來說,Nanog的穩定表達細胞株的分化狀態較控制組來得成熟,所以,Nanog不僅僅影響了肌管形成的數目,也影響了肌肉分化的程度。另外,當我們將Oct4大量表現時,MyoD以及Pax7的表現量會下降。利用轉染的方式,我們進一步的證明瞭在C2C12細胞當中,Nanog所扮演的是刺激者的角色,而Oct4所扮演的則是抑制者的角色,Nanog會形成同質聚合體,Nanog和Oct4之間具有微弱的交互作用。依據Nanog中央的homeodomain的部分,將Nanog分為三個domain,並且將Nanog的N terminal domain利用Gal-4回報系統來測試其是否具有transactivation的能力,我們發現Nanog N terminal domain的transactivation能力會依據細胞株以及promoter的不同而有所不同。另外,利用GST-pull down的方式來證明了在in vivo 的情況下Nanog、Oct4以及SMRT三者之間具有交互作用。 Embryonic stem cells are pluripotent progenitors for virtually all cell types in our body. Recent studies have shown that some transcription factors can sustain pluripotency of the stem cells. These regulators activate or repress patterns of gene expression that mediate phenotypic changes during stem cell differentiation. Nanog has recently been proposed to play a key role in maintaining stem cell pluripotency. Oct4 (Oct3), a member of the POU family of homeodomain proteins, can regulate the expression of their target genes through binding to an octameric sequence ATGCAAAT. Here, we try to explore whether over-expression of Nanog or Oct4 (Oct3) will re-establish the pluripotency of determined myoblasts and thus prevent its terminal differentiation? Using retrovirus carrying Nanog or Oct4 cDNA, we have engineered cell lines that can stably express Nanog or Oct4 or both of them. We further demonstrated that the number of the myotubes in Nanog over-expressed cell is about one fifth to that of retrovirus control infected cell. In the meantime, the number of myotubes is 59 in Nanog over-expressed cell and is 236 in retrovirus control infected cell. Morphologically, the Nanog overexpressed myotube is more matured than the retrovirus control infected cell. Our preliminary results show that Nanog actually influence the degree of differentiation not only in the number of myotube formation but also in the state of myotube maturation. Furthermore, we also found that expression of MyoD and Pax7 is downregulated in Oct4 overexpressed cells. In transient transfection reporter assays, Nanog functions as an activator, but Oct4 functions as a repressor in C2C12 cell line. We also provide evidence showing that Nanog can form homodimer complex and also interacts with Oct4 weakly. Based on the homeodomain, Nanog can be divided into three regions. In order to investigate the transactivation activity of Nanog N terminal domain, we used the well-established Gal-4 reporter system. We report here that N terminal domain of Nanog could perform different transactivation activity in different cell type under different promoter context. By using GST pull down experiment, we further demonstrated the relationship among Nanog, Oct4 and SMRT.
    顯示於類別:[生命科學研究所 ] 博碩士論文

    文件中的檔案:

    檔案 大小格式瀏覽次數


    在NCUIR中所有的資料項目都受到原著作權保護.

    社群 sharing

    ::: Copyright National Central University. | 國立中央大學圖書館版權所有 | 收藏本站 | 設為首頁 | 最佳瀏覽畫面: 1024*768 | 建站日期:8-24-2009 :::
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 隱私權政策聲明